Since it is also overexpressed in NOTCH1-induced T-ALL leukemic cells treated with chemotherapeutic drugs [163], CD44 may be considered as a valuable target for new therapies against relapsed or chemo resistant T-ALLs. This evidence concerns the gene CD44 and acute lymphoblastic leukemia.